A 78-Year-Old Man With Metastatic Melanoma and a 67-Year-Old Woman With Stage IV Melanoma : Episode 13
Second-Line Treatment Options for Patients With Metastatic or Unresectable Melanoma After Disease Progression
Hussein Tawbi, MD, PhD, explains that if a patient with metastatic melanoma and a BRAF mutation progresses after initial checkpoint inhibitors, either combination immunotherapy or MEK inhibitor therapy is considered, based on disease progression pace and pattern.
EP: 1.Case Presentation: A 78-Year-Old Man With Metastatic Melanoma
EP: 2.Common Clinical Presentations of Metastatic Melanoma
EP: 3.Significance of Biomarker and Genetic Testing in Diagnosing Metastatic Melanoma
EP: 4.Available First-Line Systemic Therapy Options for Patients With Metastatic Melanoma
EP: 5.The Role of Lymphocyte-Activation Gene 3 (LAG-3) in Metastatic Melanoma
EP: 6.Relatlimab/Nivolumab in Metastatic Melanoma: Data From the RELATIVITY-047 Trial
EP: 7.IO Monotherapy Versus Combination Dual IO Therapy for the First-Line Treatment of Metastatic Melanoma
EP: 8.Key Trial Data in the Frontline Treatment of Metastatic Melanoma
EP: 9.Managing Adverse Events in Patients With Metastatic Melanoma Receiving First-Line Systemic Therapy
EP: 10.Case Presentation: A 67-Year-Old Woman With Stage IV Melanoma
EP: 11.Available First-Line Systemic Therapy Options for Patients With Metastatic Melanoma with a BRAF Mutation
EP: 12.Nivolumab/Ipilimumab Followed by Dabrafenib/Trametinib in Metastatic Melanoma: Data From the DREAMseq Trial
Now Viewing
EP: 13.Second-Line Treatment Options for Patients With Metastatic or Unresectable Melanoma After Disease Progression
EP: 14.Clinical Pearls on the Treatment of Metastatic and Unresectable Melanoma
Recent Videos
Related Content
Similar Efficacy in Melanoma Shown in Indirect Comparison of PD-1/LAG3 vs PD-1/CTLA-4
July 16th 2024Article
During a Case-Based Roundtable® event, Michael A. Postow, MD, discussed an indirect treatment comparison of nivolumab plus relatlimab vs nivolumab plus ipilimumab in patients with advanced melanoma in the first article of a 2-part series.
Read More
